ASCO GUIDELINES Bundle

PARP Inhibitors in the Management of Ovarian Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475496

Contents of this Issue

Navigation

Page 4 of 7

Table 1. Dose Modification for PARPi Starting Dose Initial Dose Reduction 2nd Dose Reduction 3rd Dose Reduction Final Reduction Olaparib 300 mg every 12 hours 200 mg* every 12 hours 150 mg* every 12 hours Discontinue – Rucaparib 600 mg every 12 hours 500 mg every 12 hours 400 mg every 12 hours 300 mg every 12 hours Discontinue Niraparib 300 mg once daily 200 mg once daily 100 mg once daily Discontinue – Niraparib if weight <77 kg and/or platelets counts below 150,000/µL (UK based on weight <58 kg ) 200 mg once daily 100 mg once daily Discontinue – – * Dose reductions are based on general practice standard and deviate slightly from AstraZeneca's Prescribing Information

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - PARP Inhibitors in the Management of Ovarian Cancer